George D. Demetri, MD
Director of Center for Sarcoma and Bone Oncology; Senior Vice President for Experimental Therapeutics; Professor of Medicine
Dana-Farber Cancer Institute
Dr. Demetri trained at Harvard College, Stanford University School of Medicine, University of Washington, the Dana-Farber Cancer Institute and Harvard Medical School. He was instrumental in the development of Gleevec (imatinib) as one of the first targeted cancer therapies for gastrointestinal stromal tumor (GIST) as a molecularly-defined subset of sarcomas. His collaborative research efforts have contributed to worldwide regulatory approval of several other “smart drugs” for cancer, including sunitinib and regorafenib for GIST, as well as pazopanib, trabectedin, and eribulin for other sarcomas. Dr. Demetri also served on the Scientific Advisory Board of Plexxikon and a member of the team which developed the BRAF inhibitor vemurafenib (Zelboraf) as the first targeted therapy for this molecularly-defined subset of melanomas. Dr. Demetri is the current chair of the AACR Science Policy and Government Affairs Committee.